Clinical Trial: An Open-Label, Multicenter, Phase I Clinical Study Evaluating the Safety/Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of RAG-01 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette-Guérin (BCG) Therapy (China)

China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An Open-Label, Multicenter, Phase I Clinical Study Evaluating the Safety/Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of RAG-01 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette-Guérin (BCG) Therapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135488

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Fudan University Shanghai Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349954

Published by HT Digital Content Services with permission fro...